Sana Biotechnology, Inc.

NASDAQ:SANA

Biotechnology

Healthcare
$1.85 +1.23%

+$0.04 today

Market cap
$554.32M
Beta
2.16
P/E (TTM)
-3.5
EPS (TTM)
-$0.87
52W Low $2.58High $6.55

Volume 2.66M

Average 3.76M

SANA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

No reported Net Margin figures are available to summarize.

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How SANA compares with its peers on the latest reported figures

SANA Competitors Peer median
Net Margin for SANA and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 2026-0.0% +26.4 pp+352.6 pp
IPSCCentury Therapeutics, Inc.FY2025-8.8% +1912.1 pp+2509.6 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-40.9% -33.1 pp+386.2 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+417.3 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+308.8 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-597.0% +557.1 pp+299.9 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1812.1% -515.0 pp+132552.9 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2056.8% -737.9 pp-1758.5 pp
SANASana Biotechnology, Inc.FY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding SANA) -76.7%-3.4 pp+369.4 pp

Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000012.75M
Gross Profit0000(12.75M)
Gross Margin—————
Research & Development306.5M201M219.84M208.68M131.98M
Selling, General & Admin50.41M71.56M73.3M64.04M44.3M
Operating Expenses356.91M272.56M293.14M272.72M178.21M
Depreciation & Amortization11.07M15.63M24.56M17.39M12.75M
EBITDA(344.86M)(253.85M)(258.7M)(249.37M)(231.42M)
EBITDA Margin—————
Operating Income(356.91M)(272.56M)(293.14M)(272.72M)(190.96M)
Operating Margin—————
Interest Income676K3.76M9.94M10.47M3.85M
Interest Expense00000
Other Income / Expenses981K3.09M9.89M5.96M(53.21M)
Income Before Tax(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(355.93M)(269.48M)(283.26M)(266.76M)(244.17M)
Net Margin—————
EPS (Basic)(2.14)(1.43)(1.46)(1.16)(0.96)
EPS (Diluted)(2.14)(1.43)(1.46)(1.16)(0.96)
Weighted Avg Shares166.43M188.34M194.54M230.89M253.23M
Weighted Avg Shares (Diluted)166.43M188.34M194.54M230.89M253.23M

Sana Biotechnology, Inc.

NASDAQ:SANA

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.